Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 12, 2011
May 12, 2021
5ddef98b-24ad-4f80-a57b-2bd98fbf3a27
Related Documents
M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers
Guidance DocumentMarch 13, 2013Center for Drug Evaluation and Research
Q11 Development and Manufacture of Drug Substances
Guidance DocumentNovember 20, 2012Center for Drug Evaluation and Research
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
Guidance DocumentJanuary 21, 2010Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.